The protein, epithelial cadherin (E-cadherin), is known for its ability to keep cancer cells glued together, preventing them from breaking away and metastasizing. But, based on their findings, published online in PLoS ONE, the scientists suggest E-cadherin can also function as an oncogene in some cancers. An oncogene helps push cancer development and growth.
They say the findings could explain recent, puzzling observations about E-cadherin expression in breast cancer, for example. While loss of E-cadherin is generally considered a harbinger of metastasis, researchers have also found that most breast cancer that has spread retains E-cadherin expression. Ovarian tumors also have been paradoxically found to produce more and more E-cadherin as they grow.
"This surprising finding should compel us all to shift our thinking about E-cadherin," says the study's lead investigator, cancer biologist Panos Z. Anastasiadis, Ph.D. "Up to now, we have all thought that if a tumor loses E-cadherin function, that represents a movement toward metastasis. That makes sense because 50 percent of cancers don't express E-cadherin and they are linked to a worse prognosis.
"But now it appears that E-cadherin expression in a tumor could be responsible for cells growing out of control if the protein is not functioning as it should be."
Dr. Anastasiadis focuses his research on the biological factors involved in cancer metastasis. In this study, he and a research team, which included scientists from Mayo Clinic's campuses in Florida and Minnesota, examined protein expression in glioblastoma cancer cells. Glioblastoma is the most common, as well as the most dangerous, brain cancer.
"Our interest is to understand the pathways that induce glioblastoma to be so invasive," he says. "The problem with this cancer is that the tumors can be very aggressive, and single cancer cells can spread all over the brain."
Among other proteins, the researchers looked at cadherins, of which about 20 are expressed in the brain — more than in any other organ. These are transmembrane proteins that play critical roles in determining how cells bind to each other in a tissue. The researchers expected to find significant amounts of neural cadherin (N-cadherin) in the tumors, but not E-cadherin, which is expressed in epithelial rather that normal brain tissue.
In epithelial tissue, loss of E-cadherin usually represents a switch in cell behavior known as epithelial-mesenchymal transition (EMT). In EMT, cells that had been tightly bound to each other loosen up, due to loss of E-cadherin, and other proteins — including other members of the cadherin superfamily — then promote migration of individual cells away from a cancer cluster. Drugs are being developed that target this EMT switch, says Dr. Anastasiadis.
Given these facts, the researchers say that what they found surprised them. While N-cadherin was expressed in most human brain tumor cell lines — and N-cadherin is potentially oncogenic — some also expressed E-cadherin. They also found those cells that expressed E-cadherin acted more aggressively than brain cancer that did not express the protein. The researchers then validated their findings in animal studies. Finally, they performed an experiment in which they removed E-cadherin expression from glioblastoma cells and found these cells had a reduced ability to move, and grew at a much slower pace.
"E-cadherin expressed in these glioblastomas did not function to keep cells stuck together. Instead, they promoted tumor growth and migration," Dr. Anastasiadis says. "This is the complete opposite of what we have known about E-cadherin. For some reason, in these brain cells, E-cadherin expression is linked to aggressive cell behavior and poor prognosis."
The findings suggest "cadherins, as a whole class of proteins, need to be studied in more detail," he says. "E-cadherin expressed in glioblastoma functioned like an oncogene and it could be doing the same in many breast, ovarian, and other tumors found elsewhere in the body.
"Understanding what causes the switch in E-cadherin function from a tumor suppressor to an oncogene, and how to block it, will be critical," concludes Dr. Anastasiadis. "But the bottom line is that we cannot view E-cadherin simply as a tumor suppressor anymore."
The study was funded by the National Institutes of Health, the Accelerate Brain Cancer Cure Foundation, and a Daniel Foundation training grant. Co-authors from Mayo Clinic's sites in Florida and Minnesota include Laura Lewis-Tuffin, Ph.D., Fausto Rodriquez, M.D., Caterina Giannini, M.D., Ph.D., Bernd Scheithauer, Brian Necela, Ph.D., and Jann Sarkaria, M.D. The authors declare no conflicts of interest.
About Mayo Clinic
For more than 100 years, millions of people from all walks of life have found answers at Mayo Clinic. These patients tell us they leave Mayo Clinic with peace of mind knowing they received care from the world's leading experts. Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. At Mayo Clinic, a team of specialists is assembled to take the time to listen, understand and care for patients' health issues and concerns. These teams draw from more than 3,700 physicians and scientists and 50,100 allied staff that work at Mayo Clinic's campuses in Minnesota, Florida, and Arizona; and community-based providers in more than 70 locations in southern Minnesota, western Wisconsin and northeast Iowa. These locations treat more than half a million people each year. To best serve patients, Mayo Clinic works with many insurance companies, does not require a physician referral in most cases and is an in-network provider for millions of people. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your general health information.
Kevin Punsky | EurekAlert!
A novel socio-ecological approach helps identifying suitable wolf habitats
17.02.2017 | Universität Zürich
New, ultra-flexible probes form reliable, scar-free integration with the brain
16.02.2017 | University of Texas at Austin
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
17.02.2017 | Medical Engineering
17.02.2017 | Medical Engineering
17.02.2017 | Health and Medicine